VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus rating of “Reduce” from the five analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $0.95.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd.

Institutional Investors Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VTGN. Bank of America Corp DE raised its stake in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after purchasing an additional 19,331 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics during the 1st quarter worth about $25,000. Marshall Wace LLP bought a new position in shares of VistaGen Therapeutics during the 2nd quarter worth about $69,000. Jane Street Group LLC acquired a new position in shares of VistaGen Therapeutics during the second quarter valued at about $190,000. Finally, Dimensional Fund Advisors LP raised its position in shares of VistaGen Therapeutics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after buying an additional 24,655 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Stock Up 1.5%

VTGN stock traded up $0.00 during mid-day trading on Thursday, reaching $0.25. 157,697 shares of the stock traded hands, compared to its average volume of 1,410,047. VistaGen Therapeutics has a 52 week low of $0.20 and a 52 week high of $5.14. The business has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.55. The firm has a market capitalization of $10.13 million, a PE ratio of -0.13 and a beta of 0.40.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $0.40 million. During the same quarter in the previous year, the firm posted ($1.67) earnings per share. On average, equities research analysts anticipate that VistaGen Therapeutics will post -1.32 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.